Document is current
Any future updates will be listed below
-
Authors
Kameda, Hideto https://orcid.org/0000-0002-4330-5782
Ishii, Kentaro https://orcid.org/0009-0001-7669-4622
Kiriyama, Junna https://orcid.org/0009-0008-2468-5311
Mikami, Toshiaki https://orcid.org/0009-0004-0568-316X
Uratsuji, Hideya https://orcid.org/0000-0003-2811-0474
Morita, Akimichi https://orcid.org/0000-0001-8372-3754
-
Funding
Funding for this research was provided by:
Novartis Pharma K.K
- License Information
-
More Information
Article History
Received: 1 November 2024
Accepted: 27 January 2025
First Online: 12 March 2025
Declarations
:
: Hideto Kameda has received speaker’s fees from AbbVie, Asahi Kasei, AstraZeneca, Boehringer, Bristol Myers Squibb, Eisai, Eli Lilly, Johnson & Johnson Innovative Medicine, Mitsubishi-Tanabe, Novartis, Pfizer and UCB, consultancy fees from AbbVie and Sanofi, and research grants from Asahi Kasei, Boehringer, Chugai, Eisai, Mitsubishi-Tanabe, Pfizer and Taisho. Kentaro Ishii, Junna Kiriyama, Toshiaki Mikami are employees of Novartis, who manufactures and co-markets secukinumab in Japan. Hideya Uratsuji is an employee of Maruho, who co-markets secukinumab in Japan. Akimichi Morita has received research grants, consultancy fees or speaker’s fees from AbbVie, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Johnson & Johnson Innovative Medicine, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Nippon Kayaku, Novartis, Pfizer, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, UCB Japan, and Ushio.
: The study complied with all relevant international and Japanese national legislation on medical research and data privacy. In particular, it complied with the Declaration of Helsinki and with the Japanese Act on the Protection of Personal Information. The requirement for ethics approval and informed consent is regulated by the Japanese Pharmaceuticals and Medical Devices Agency guidelines for conducting pharmaco-epidemiological research using medical databases. In accordance with these guidelines, the study was not subject to an ethics review as anonymized processed information has already been created by the data provider (as stipulated in Article 2, Paragraph 6 of the Personal Information Protection Act). Collecting patient consent to participate is not relevant to this study since the data came from an administrative healthcare insurance database in which all patient data is anonymized and the individual patients whose data is used cannot be identified.
